pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Aug 5·1 min read
save

WuXi AppTec posts six-month revenue higher than Lonza for first time

Aug 5, 2026·read at Endpoints ↗Positive

WuXi AppTec, a Chinese contract manufacturing organization, has reported that its revenue over the most recent six-month period exceeded that of Swiss CDMO Lonza for the first time.

The increase comes despite heightened scrutiny from the U.S. Department of Defense, which has been reviewing the company's operations.

The company’s growth suggests it continues to expand its role in the global pharmaceutical manufacturing market, while Lonza’s revenue lag indicates competitive pressure.

No further financial details were disclosed in the brief report.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “In a first, WuXi AppTec surpasses Lonza’s six-month revenue”

read at Endpoints ↗
84 words · retrieved Aug 5
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
CRO/CDMO3

related stories

  • 3d agoSionna says good-bye to 46% of staffers, including execBioSpace
  • Jul 27FDA has recommitted to adcomms—but to what end?BioSpace
  • Jul 23Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansionEndpoints
  • Jul 23Biopharma layoffs must double in H2 for 2026 to match 2025 cutsBioSpace
  • Jul 22House passes bill directing FDA to update animal testing rulesFierce Biotech